QQQ1.86%

Trending

MSFT9.72%

Info

home Symbol XBInews

Exchange: NYSEArca·Updated 09:04 AM EDT

XBISPDR S&P Biotech ETF

$148.40

$0.49

(0.33%)

Pre-Market

Prev Close $147.91

News·Capricor’s FDA Fate Divides Wall Street And Investors: One Analyst Sees A $2 Stock But Retail Holds Out Hope

Vol33,837.00

52W High$165.71

52W Low$84.39

News

all

press releases

Capricor’s FDA Fate Divides Wall Street And Investors: One Analyst Sees A $2 Stock But Retail Holds Out Hope

Capricor stock is headed for its worst week on record after a negative FDA advisory committee vote rattled Wall Street.

Stocktwits

More News

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Zacks

VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress

Viking has no approved drug products, and in the pre-revenue phase, investor attention centers almost entirely on clinical progress.

Stocktwits

Capricor Faces Make-Or-Break FDA Panel For Duchenne Cell Therapy — Experts And Investors Weigh In

Earlier this week, the FDA questioned how Capricor analyzed results from its late-stage HOPE-3 trial, sending the stock sharply lower and raising doubts about a potential approval.

Stocktwits

Capricor’s DMD Therapy Gets Lancet Backing Ahead Of August FDA Showdown – CEO Says Publication ‘Reinforce Our Confidence’ For Approval

The publication comes ahead of a crucial U.S. Food and Drug Administration advisory committee meeting and the agency’s final approval decision in August.

Stocktwits

REPL Stock Clocks Worst Day In Over 3 Months — New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug

Wall Street now views the path to clearance for RP1 as increasingly uncertain following two prior rejections.

Stocktwits

ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff

Earlier on Tuesday, Altimmune said the mid-stage RECLAIM trial met its main goal and key secondary goals.

Stocktwits

This Analyst Slashed CAPR Stock’s Target By 86% – But, Retail Bulls Say Setup Offers An Attractive Risk-Reward

Alliance Global said that the upcoming FDA advisory committee meeting now appears to be an ‘uphill battle’ for Capricor.

Stocktwits

FDA Staff Raise Concerns On Replimune’s Skin Cancer Drug – REPL Stock Crashes 32% Today Ahead Of Advisory Meeting This Week

Replimune’s melanoma treatment application, which was accepted by the FDA after a third submission, has come under renewed scrutiny after agency reviewers raised concerns about the trial design and the reliability of the reported response rates.

Stocktwits

Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10%

Altimmune’s Phase 2 trial showed Pemvidutide reduced heavy drinking by 4.20 days per week compared with the placebo’s 2.75 days.

Stocktwits

Advertisement|Remove ads.